Triple Negative Breast Cancer Clinical Trials

683 clinical trials for Triple Negative Breast Cancer across international registries, including 186 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer（UPGRADE-TNBC） — RECRUITING · PHASE2
• Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors — RECRUITING · PHASE1
• Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer — RECRUITING · PHASE2
• GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours — RECRUITING · PHASE1
• A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors — RECRUITING · PHASE1
• A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors — RECRUITING · PHASE1
• The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) — RECRUITING · PHASE1
• Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) — RECRUITING · PHASE3
• Breast Cancer PSMA PET — RECRUITING · PHASE1
• A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors — RECRUITING · PHASE1
• Paclitaxel Oral Solution in Triple Neagtive Breast Cancer Neoadjuvant Therapy: A Dose-Finding Study — RECRUITING · PHASE1
• Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) — RECRUITING · PHASE1
• Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer — RECRUITING · PHASE1
• NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III) — RECRUITING · PHASE3
• Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies — RECRUITING · PHASE2
• Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers — RECRUITING · PHASE1
• Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors — RECRUITING · PHASE1
• Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells — RECRUITING · PHASE1
• A Phase 1 of CTX-8371 in Patients With Advanced Malignancies — RECRUITING · PHASE1
• Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC — RECRUITING · PHASE2
• A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer — RECRUITING · PHASE2
• Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer — RECRUITING · PHASE3
• Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE) — RECRUITING · NA
• A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors — RECRUITING · PHASE1
• PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer — RECRUITING · PHASE1
• Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies — RECRUITING · PHASE1
• Sacituzumab Govitecan In TNBC — RECRUITING · PHASE2
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) — RECRUITING · PHASE3
• Granzyme B-PET: Predicting Immunotherapy Efficacy in TNBC — RECRUITING
• A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors — RECRUITING · PHASE1
• Predicting Response to Immunochemotherapy in Early Triple Negative Breast Cancer — RECRUITING
• First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer — RECRUITING · PHASE1
• A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors — RECRUITING · PHASE1
• A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors — RECRUITING · PHASE1
• A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors — RECRUITING · PHASE1
• A Study of LY4175408 in Participants With Advanced Cancer — RECRUITING · PHASE1
• Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan — RECRUITING · PHASE1
• Study of XB010 in Subjects With Solid Tumors — RECRUITING · PHASE1
• A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types — RECRUITING · PHASE1
• Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors — RECRUITING · PHASE1
• A Nurse-Led, Coping and Supportive Intervention for Patients With Triple-Negative Breast Cancer — RECRUITING · NA
• THE-0504 in Patients With Solid Tumors — RECRUITING · PHASE1
• A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4 — RECRUITING · PHASE1
• MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors — RECRUITING · PHASE1
• ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer — RECRUITING · PHASE2
• Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors — RECRUITING · PHASE1
• Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI) — RECRUITING · PHASE1
• Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing — RECRUITING
• Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy — RECRUITING · PHASE2
• Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer — RECRUITING · PHASE1

Refine this search